Louisville Medicine Volume 66, Issue 5 | Page 9

PUBLIC HEALTH KENTUCKY DEPARTMENT OF PUBLIC HEALTH Updates Hepatitis C Screening Recommendations Lori Caloia, MD I n April 2018, KRS 214.160 was amended to establish a requirement that all pregnant women in Kentucky be tested for hepatitis C virus (HCV). This statute also requires that children born to women who have a positive HCV result be reported to the lo- cal health department and recommends that they have follow up HCV testing. This article is a summary of the most recent Kentucky Department of Public Health (KDPH) HCV screening, testing and management recommendations and resources for care. The HCV updated screening recommendations from the KDPH can be found at the following website: https://bit.ly/2QKfx6P. More than 70 percent of individuals with hepatitis C report injec- tion drug use (8), and an estimated incidence of HCV infection in people who inject drugs (PWID) was 55.5 percent (range 43.8 to 67 percent) (10). In response to these increasing HCV rates in Kentucky, particularly affecting women of childbearing age and their offspring, in April 2018, the Commonwealth amended SB 250 KRS 214.160 to establish that all pregnant women in Kentucky be tested for hepatitis C, and recommended testing for children born from a pregnant woman who has a positive hepatitis C test result. BACKGROUND » » Adults born during 1945 through 1965 should be tested once (without prior ascertainment of HCV risk factors) (11) » » All pregnant women » » HCV-testing is recommended for those who have the following risk factors: o Have history of injection or intranasal drug use, or use currently o Unregulated body piercing and/or tattoos o Sexual contact with a known HCV-positive person o History of high risk sexual behavior o History of sexually transmitted infection o History of incarceration o Have certain medical conditions, including persons: • who received clotting factor concentrates produced before 1987 • who were ever on long-term hemodialysis • who have HIV infection • who have hepatitis B infection o Were prior recipients of transfusions or organ transplants, including persons who: • were notified that they received blood from a donor who later tested positive for HCV infection • received a transfusion of blood, blood components or an organ transplant before 1992 » » HCV - testing based on a recognized exposure is recommended for: o Health care, emergency medical and public safety workers after needle sticks, sharps or mucosal exposures to HCV-pos- itive blood (note: the risk of HCV infection after needlestick or sharps exposure to HCV-positive blood is estimated at Hepatitis C, a blood-borne disease, is usually a chronic viral infection with few early symptoms. Only 20 to 30 percent of acutely infected individuals experience fatigue, abdominal pain, poor appetite, or jaundice (1), most with symptom onset two to 12 weeks following exposure (range two to 26 weeks)(2, 3). Approximately 15 to 20 percent of acutely infected persons clear the infection(4, 5), with many predictive variables for spontaneous clearance, including jaundice, elevated ALT level, hepatitis B virus surface antigen (HB- sAg) positivity, female sex, younger age, HCV genotype 1 and host genetic polymorphisms (4, 5). HCV infection becomes chronic in approximately 75 to 85 per- cent of cases (4, 5), and patients may develop fibrosis, hepatocellular carcinoma, and in 10 to 20 percent of cases, cirrhosis. Chronic HCV infection is the leading indication for liver transplants in the Unit- ed States (6). Prior infection with HCV infection does not protect against later infection with the same or different genotypes of the virus. Presently no vaccine for hepatitis C is available. The Center for Disease Control (CDC) estimates that 3.5 million persons are living with chronic HCV infection in the United States (7). In 2016, the estimated incidence of acute hepatitis C infection in the US was one case per 100,000 and more than double that in Kentucky, where the incidence was 2.3 cases per 100,000. Both are likely underreported due to inadequate surveillance and neither is near the Healthy People 2020 goal of < 0.25 cases per 100,000 (8). The hepatitis C epidemic among people who inject drugs con- tinues to spread throughout Kentucky and the US in both urban and rural areas, especially among people in their 20s and 30s (8,9). WHO SHOULD BE TESTED FOR HCV INFECTION? According to current KDPH guidelines, HCV testing is recom- mended for anyone at increased risk for HCV infection, including: OCTOBER 2018 7